Merck Obtains Distribution Rights to Sucralose from Tate & Lyle

Merck and EMD Chemicals, a U.S. subsidiary of Merck KGaA, will market sucralose under their own label as of April 1, 2009 and in conjunction with the EMPROVE service package. Business activities will focus on the United States, Europe and certain parts of Asia. Sucralose will be available in powder and granular form.

17/02/09 Merck KGaA and Tate & Lyle announced that they have entered into a distribution agreement for sucralose. According to the agreement, Tate & Lyle has granted Merck the rights to distribute sucralose in the global pharmaceutical market with the exception of certain countries.

Tate & Lyle is the original developer of sucralose, a high-intensity sweetener that is used as a sugar substitute in the pharmaceutical industry, among others. A spokesperson for the company told FoodIngredientsFirst.com that the benefit for the Tate & Lyle busines is that it will allow them to expand their pharmaceutical presence globally, “as Merck is the right partner to compliment T&L's own marketing activity focusing on food and beverages”.

Merck and EMD Chemicals, a U.S. subsidiary of Merck KGaA, will market sucralose under their own label as of April 1, 2009 and in conjunction with the EMPROVE service package. Business activities will focus on the United States, Europe and certain parts of Asia. Sucralose will be available in powder and granular form.

“We sought a distribution partner for sucralose because we want to expand our global presence in the pharmaceutical market“, said Karl Kramer, President of the Sucralose Division, from Tate & Lyle. “We chose Merck because of the company’s growth-oriented strategy, global marketing structures and excellent customer proximity.”

“We are honored that such a distinguished manufacturer has selected us to represent their premier product line,” said Jens Rousselot, Senior Manager for Pharmaceutical Raw Materials at Merck.

“Sucralose will complement our current portfolio of excipients and strengthen our market position as a supplier of raw materials for pharmaceutical final formulation.”